Fulgent Genetics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 1,313

Employees

  • Stock Symbol
  • FLGT

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $19.52
  • (As of Tuesday Closing)

Fulgent Genetics General Information

Description

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Contact Information

Formerly Known As
Fulgent Diagnostics, Fulgent Diagnostics, Inc.
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 4399 Santa Anita Avenue
  • Suite 205
  • El Monte, CA 91731
  • United States
+1 (626)
Primary Industry
Other Healthcare Services
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 4399 Santa Anita Avenue
  • Suite 205
  • El Monte, CA 91731
  • United States
+1 (626)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fulgent Genetics Stock Performance

As of 24-Jun-2025, Fulgent Genetics’s stock price is $19.52. Its current market cap is $594M with 30.4M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$19.52 $19.33 $14.57 - $25.11 $594M 30.4M 341K -$1.33

Fulgent Genetics Financials Summary

As of 31-Mar-2025, Fulgent Genetics has a trailing 12-month revenue of $292M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 267,924 357,370 394,916 353,872
Revenue 292,448 283,470 289,213 618,968
EBITDA (33,011) (58,502) (169,066) 212,076
Net Income (40,776) (42,708) (167,825) 143,403
Total Assets 1,205,744 1,219,964 1,235,328 1,386,053
Total Debt 7,657 8,468 15,251 38,937
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Fulgent Genetics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Fulgent Genetics‘s full profile, request access.

Request a free trial

Fulgent Genetics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actio
Other Healthcare Services
El Monte, CA
1,313 As of 2024

Luxembourg, Luxembourg
 

Wilmington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Fulgent Genetics Competitors (18)

One of Fulgent Genetics’s 18 competitors is Eurofins Scientific, a Corporation company based in Luxembourg, Luxembourg.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eurofins Scientific Corporation Luxembourg, Luxembourg
Charles River Laboratories International Formerly PE-Backed Wilmington, MA
Crown Bioscience Formerly VC-backed San Diego, CA
Quest Diagnostics Corporation Secaucus, NJ
NeoGenomics Laboratories Corporation Fort Myers, FL
You’re viewing 5 of 18 competitors. Get the full list »

Fulgent Genetics Patents

Fulgent Genetics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250108106-A1 Nanoencapsulated pharmaceutical composition and use thereof Pending 14-Mar-2022
US-20240002383-A1 Compounds and their use as vaccine adjuvants Pending 24-May-2021
US-20240132493-A1 Imidazopyridine derivatives as sting agonists Pending 24-May-2021
US-20240016754-A1 Pharmaceutical composition containing taxane nanoaggregates and use thereof Pending 15-Feb-2021
AU-2018217318-A1 Nanoparticles containing a taxane and their use Inactive 05-Feb-2013 A61K9/5146
To view Fulgent Genetics’s complete patent history, request access »

Fulgent Genetics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fulgent Genetics Investments & Acquisitions (8)

Fulgent Genetics’s most recent deal was a Merger/Acquisition with Fulgent Pharma for . The deal was made on 07-Nov-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Fulgent Pharma 07-Nov-2022 Merger/Acquisition Drug Discovery
Inform Diagnostics 18-Apr-2022 Merger/Acquisition Laboratory Services (Healthcare)
Spatial Genomics 18-Feb-2022 Early Stage VC Discovery Tools (Healthcare)
LAMH 11-Sep-2021 Later Stage VC Laboratory Services (Healthcare)
CSI Laboratories 09-Aug-2021 Merger/Acquisition Laboratory Services (Healthcare)
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Fulgent Genetics ESG

Risk Overview

Risk Rating

Updated October, 15, 2024

17.34 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Healthcare

Industry

of 564

Rank

Percentile

Medical Services

Subindustry

of 93

Rank

Percentile

To view Fulgent Genetics’s complete esg history, request access »

Fulgent Genetics Exits (1)

Fulgent Genetics’s most recent exit was on 07-Nov-2022 from Fulgent Pharma. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Fulgent Pharma 07-Nov-2022 Completed
To view Fulgent Genetics’s complete exits history, request access »

Fulgent Genetics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Fulgent Pharma El Monte, CA 2016
CSI Laboratories Alpharetta, GA 1997

Fulgent Genetics FAQs

  • When was Fulgent Genetics founded?

    Fulgent Genetics was founded in 2011.

  • Where is Fulgent Genetics headquartered?

    Fulgent Genetics is headquartered in El Monte, CA.

  • What is the size of Fulgent Genetics?

    Fulgent Genetics has 1,313 total employees.

  • What industry is Fulgent Genetics in?

    Fulgent Genetics’s primary industry is Other Healthcare Services.

  • Is Fulgent Genetics a private or public company?

    Fulgent Genetics is a Public company.

  • What is Fulgent Genetics’s stock symbol?

    The ticker symbol for Fulgent Genetics is FLGT.

  • What is the current stock price of Fulgent Genetics?

    As of 24-Jun-2025 the stock price of Fulgent Genetics is $19.52.

  • What is the current market cap of Fulgent Genetics?

    The current market capitalization of Fulgent Genetics is $594M.

  • What is Fulgent Genetics’s current revenue?

    The trailing twelve month revenue for Fulgent Genetics is $292M.

  • Who are Fulgent Genetics’s competitors?

    Eurofins Scientific, Charles River Laboratories International, Crown Bioscience, Quest Diagnostics, and NeoGenomics Laboratories are some of the 18 competitors of Fulgent Genetics.

  • What is Fulgent Genetics’s annual earnings per share (EPS)?

    Fulgent Genetics’s EPS for 12 months was -$1.33.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »